

Relationship between COVID-19 and patients with chronic disease: A review

Jwan A. Ali¹, Ilham A. Bunyan^{*2} Haythem A. Alsayigh³

¹Department of Human Anatomy, College of Medicine, University of Babylon, Iraq

²Department of Microbiology, College of Medicine, University of Babylon, Iraq

³Department of Human Anatomy, College of Medicine, University of Babylon, Iraq

*Corresponding Author

Ilham A. Bunyan

Ilhamalsiedi2008@gmail.com

Abstract

COVID-19 is profoundly irresistible sickness where the primary tainted case revealed in Wuhan city-China; at that point it was spread around the world. The causative operator has a place with novel encompassed single straight positive-sense abandoned RNA Coronavirus, which is likewise called SARS-CoV-2 and has a fondness to lung cells. The hereditary examination of SARS-CoV-2, proposed that this novel virus strain might have evolved from animals. Root by recombination between a bat SARS-like CoV and a coronavirus of obscure birthplace. The capacity of fast spread of SARS-CoV-2 infection from individual to other is comparable or much more than to other human infections like flu or plague prompting be declared as a pandemic by WHO in 2020. The realities in this audit lead to propose that as a rule the demise in SARS-CoV-2 may happen through loss of fundamental fiery reaction control which prompting lung injury followed by pneumonia, intense respiratory misery condition (ARDS) and respiratory disappointment, thus the passing particularly in old patients with incessant infection. Individuals with hypertension are likewise marginally bound to bite the dust from coronavirus. Their hazard is about 6% higher than the general populace. "Numerous patients with extreme COVID-19 are those with coinciding, constant conditions, including hypertension and diabetes. Both of these expansions the danger of kidney infection

Keywords: *Covid19; Health; disease; SARS*

DOI: <http://doi.org/10.36295/ASRO.2021.24467>

Page(s): 573-579

Volume/ Issue: Volume: 24/ Issue: 04

Introduction

Clinical features

The most widely recognized side effects of COVID-19 incorporate fever, discomfort, dry hack and brevity of breath. Different side effects incorporate nasal blockage, cerebral pain, conjunctivitis, sore throat, loose bowels, loss of taste or smell, skin rash or dis-coloration of fingers or toes. A few people become tainted yet just have exceptionally gentle or vague indications ^[1-4]. As indicated by the World Health Organization, about 20% of the cases may create genuine disease with breathing trouble. Individuals of more seasoned age or having hidden infections (for example hypertension, heart and lung issues, diabetes, renal disappointment or disease) are at a higher danger of decay into genuine condition ^[5].

High Blood Pressure Risks

Information from China and Italy - nations hit right on time by the infection - show higher danger of COVID-19 contaminations and difficulties in individuals with hypertension ^[6]. In China, 25% to half of individuals who came to emergency clinics with coronavirus had hypertension or another wellbeing condition like malignant growth, diabetes, or lung infection. In Italy, over 99% of individuals who've kicked the bucket from the infection had one of these conditions and 76% of them had hypertension

^[7]Individuals with hypertension are likewise marginally bound to bite the dust from coronavirus. Their hazard is about 6% higher than the general populace. A more fragile insusceptible framework is one explanation individuals with hypertension and other medical issues are at higher hazard for coronavirus. Long haul wellbeing conditions and maturing debilitate safe framework so it's less ready to fend off the infection ^[8]. About 66% of individuals more than 60 have hypertension. Another chance is that the higher hazard comes not from hypertension itself, however from specific medications used to treat it - ACE inhibitors and angiotensin receptor blockers (ARBs). This is only a hypothesis, since there's no examination yet on what sway, assuming any, these drugs may have on COVID-19 ^[9].

The hypothesis depends on the way that ACE inhibitors and ARBs raise levels of a catalyst called ACE2 in the body, and to contaminate cells, the COVID-19 infection must append itself to ACE2. Until more research comes out, the American College of Cardiology and American Heart Association suggest that continue taking hypertension medication as endorsed ^[10]. On the off chance that they don't, it could raise the hazard for a respiratory failure or stroke, placing in the medical clinic similarly as coronavirus cases are coming in. While pneumonia is the most widely recognized entanglement of the infection, it can likewise harm the cardiovascular framework. That is the reason individuals with hypertension, coronary illness, and cardiovascular breakdown are in danger. Hypertension has been known to decline the danger of genuine side effects, yet the investigation, distributed Thursday in the European Heart Journal, shows exactly how awful the hazard is ^[11].

The worldwide group of scientists drove by Fei Li and Ling Tao of the division of cardiology at Xijing Hospital in Xian, China, considered the records of 2,866 patients rewarded in Wuhan, where the coronavirus pandemic was first taken note. Just shy of 30% of them had hypertension. "Not long after we began to treat Covid-19 patients toward the beginning of February in Wuhan, we saw that about portion of the patients who kicked the bucket had hypertension, which was an a lot higher rate contrasted with those with just mellow Covid-19 side effects," Tao said in an announcement ^[12]. The group found that 4% of patients with hypertension kicked the bucket, contrasted with 1.1% of those with ordinary pulse. After certain alterations for contrasts among the patients, that worked out to a multiplied danger of biting the dust for the patients with hypertension, and 7.9% of patients who had quit taking their circulatory strain meds kicked the bucket. The analysts at that point went to a pool of clinical records from 2,300 additional patients to see whether it made a difference which circulatory strain drugs they took ^[13].

There have been stresses over medications known as ACE-2 inhibitors and ARBs, which utilize a system like the pathway utilized by the coronavirus to get into cells. A few specialists dreaded those medications could make it simpler for the infection to taint cells ^[14]. Be that as it may, the group didn't discover proof of that. "We were very astonished that these outcomes didn't bolster our underlying theory; actually, the outcomes were the other way, with a pattern for ACE inhibitors and ARBs," Tao said. "In this manner, we propose that patients ought not stop or change their standard antihypertensive treatment except if taught by a doctor ^[15].

Kidney failure risk

A few people enduring with serious instances of COVID-19 are giving indications of kidney harm, even the individuals who had no hidden kidney issues before they were tainted with the coronavirus ^[16]. Early reports state that up to 30% of patients hospitalized with COVID-19 in China and New York created moderate or extreme kidney injury. Reports from specialists in New York are stating the rate could be higher. Indications of kidney issues in patients with COVID-19 remember elevated levels of protein for the pee and irregular blood work ^[17].

The kidney harm is, now and again, sufficiently extreme to require dialysis. A few medical clinics encountering floods of patients who are sick with COVID-19 have announced they are running low on the machines and clean liquids expected to play out these kidney techniques. "Numerous patients with

extreme COVID-19 are those with coinciding, incessant conditions, including hypertension and diabetes. Both of these expansion the danger of kidney sickness," Sperati says^[18]. In any case, Sperati and different specialists are additionally observing kidney harm in individuals who didn't have kidney issues before they got tainted with the infection. The effect of COVID-19 on the kidneys isn't yet clear. Here are a few prospects specialists and analysts are investigating: The infection itself taints the cells of the kidney. Kidney cells have receptors that empower the new coronavirus to join to them, attack, and make duplicates of itself, conceivably harming those tissues^[19].

Comparable receptors are found on cells of the lungs and heart, where the new coronavirus has been appeared to cause injury. Another chance is that kidney issues in patients with the coronavirus are because of unusually low degrees of oxygen in the blood, an aftereffect of the pneumonia generally observed in extreme instances of the ailment^[20]. The body's response to the disease might be dependable also. The invulnerable reaction to the new coronavirus can be outrageous in certain individuals, prompting what is known as a cytokine storm. At the point when that occurs, the resistant framework sends a surge of cytokines into the body^[21]. Comparable receptors are found on cells of the lungs and heart, where the new coronavirus has been appeared to cause injury. Another chance is that kidney issues in patients with the coronavirus are because of strangely low degrees of oxygen in the blood, an aftereffect of the pneumonia regularly observed in extreme instances of the illness^[22]. The kidneys resemble sift that screen through poisons, additional water and waste items from the body. COVID-19 can make little clusters structure in the circulation system, which can stop up the littlest veins in the kidney and impede its capacity^[23].

Diabetes as a risk factor

They ought to likewise be increasingly cautious about controlling their glucose and abstaining from changing their meds without speaking with a doctor. A few nutrients and minerals assume a job in improving the capacity of the safe framework, however the subjective and aimless utilization of enhancements containing these micronutrients may cause issue in the body's capacity^[24]. In this manner, if an individual isn't supplement inadequate, it is smarter to give supplements by food sources and abstain from taking enhancements without talking with a specialist. Late examinations show that there is no particular method to keep the insusceptible framework from tainting individuals with the COVID-19, particularly individuals with diabetes^[25].

All in all, unwinding, satisfactory rest, and appropriate sustenance can improve the invulnerable framework. Diabetes is a hazard factor for hospitalization and mortality of the COVID-19 contamination. Diabetes was a comorbidity in 22% of 32 non-survivors in an investigation of 52 serious consideration patients^[26]. In another investigation of 173 patients with extreme infection, 16.2% had diabetes, and in further investigation of 140 hospitalized patients, 12% had diabetes. When looking at serious consideration and non-escalated care patients with COVID-19, there has all the earmarks of being a twofold increment in the rate of patients in concentrated consideration having diabetes^[27]. Mortality is by all accounts about triple higher in individuals with diabetes contrasted and the general mortality of COVID-19 in China.

The quantity of comorbidities is an indicator of mortality in COVID-19. Notwithstanding diabetes, the other basic comorbidities were hypertension, in about 20% of cases, cardiovascular malady (16%), and lung ailment (6%)^[28]. To be sure, individuals with diabetes are a high-hazard bunch for extreme malady. Eminently, diabetes was additionally a hazard factor for serious illness and mortality in the past SARS, MERS (Middle East respiratory condition) coronavirus diseases and the extreme flu A H1N1 pandemic in 2009^[29]. People with diabetes are at expanded danger of diseases including flu and for related confusions, for example, auxiliary bacterial pneumonia. Diabetes patients have impeded insusceptible reaction to contamination both comparable to cytokine profile and to changes in resistant reactions including T-cell and macrophage enactment^[30].

Poor glycaemic control impedes a few parts of the safe reaction to viral contamination and furthermore to the potential bacterial optional disease in the lungs. Almost certainly, a considerable lot of the patients with diabetes in China have been in poor metabolic control when tainted by COVID-19^[31]. Numerous patients with type 2 diabetes are corpulent and stoutness is likewise a hazard factor for extreme disease. It was outlined during the flu A H1N1 pestilence in 2009 that the sickness was progressively extreme and had a more extended term in about twofold more patients with stoutness who were then rewarded in escalated care units contrasted and foundation populace, particularly, metabolic dynamic stomach corpulence is related with higher hazard^[32]. The unusual discharge of adipokines and cytokines like TNF-Alpha and interferon portray a constant second rate in stomach heftiness and may actuate an impeded resistant reaction. Individuals with serious stomach heftiness additionally have mechanical respiratory issues, with diminished ventilation of the basal lung segments expanding the danger of pneumonia just as decreased oxygen immersion of blood^[33].

Large subjects additionally have an expanded asthma hazard, and those patients with weight and asthma have more indications, progressively visit and serious intensifications and decreased reaction to a few asthma drugs^[34]. Ultimately, late diabetic entanglements, for example, diabetic kidney malady and ischaemic coronary illness may confuse the circumstance for individuals with diabetes, making them frailer and further expanding the seriousness of COVID-19 ailment and the requirement for care, for example, intense dialysis. A few discoveries show that COVID-19 could cause intense cardiovascular injury with cardiovascular breakdown, prompting crumbling of course^[35]. The most incessant comorbidities to COVID 19 are hypertension and diabetes. The two ailments are frequently rewarded with angiotensin-changing over proteins (ACE) inhibitors. Coronavirus ties to target cells through angiotensin-changing over protein 2 (ACE2), which communicated in the epithelial cells in the lungs, veins and in the digestive system^[36]. In patients rewarded with ACE and angiotensin II receptor blockers, articulation of ACE2 is expanded. In this way, it has been proposed that ACE2 articulation might be expanded in these two gatherings of patients with hypertension and diabetes, which could encourage contamination with COVID-19 and increment the danger of extreme illness and casualty^[37].

Lung frailer

Like other respiratory malady prompting infections, for example, SARS, MERS, and network gained pneumonia (CAP), COVID-19 typically first influences the lungs. Early side effects incorporate fever, hack, and brevity of breath. These side effects can show up inside two days or as long as 14 days after contact with the infection^[38]. The COVID-19 seriousness shifts from mellow or asymptomatic to extreme or now and again deadly. More established individuals and those with interminable maladies have all the earmarks of being at a higher danger of genuine manifestations. This fluctuation is additionally found in the impact of COVID-19 on the lungs^[39]. A few people may have just mellow respiratory side effects while others may create pneumonia, which doesn't compromise an individual's life.

A few people additionally experience the ill effects of extreme lung harm. As indicated by look into, what we regularly find in individuals who are seriously contaminated with COVID-19 is respiratory pain disorder^[40]. These conditions are not brought about by the infection alone and can be activated by an assortment of occasions, including diseases, injury, sepsis, and weakness. These conditions harm the lungs, prompting liquid spillage from little veins in the lungs^[41]. While there is an absence of data about the kind of harm brought about by COVID-19 in the lungs, another report has indicated that comparative harm can happen with SARS and MERS. All things considered, individuals experienced issues in breathing five days after the beginning of indications^[42]. By and large, eight days after the beginning of side effects. The treatment for respiratory misery disorder includes the utilization of oxygen and mechanical breath to ingest more oxygen into the blood^[43].

There is no particular treatment for respiratory trouble condition and clinical staff must put forth a valiant effort to help the patient during this procedure with the goal that the body recuperates and the

safe framework deals with basic occasions ^[44]. A great deal of patients are detailing agony or distress in the chest during COVID-19 and it is a significant normal manifestation; in an ongoing UK report more than 1 out of 10 patients with COVID-19 had chest torment ^[45].

It is no doubt brought about by irritation of the coating of the lung (in some cases called pleurisy) in spite of the fact that torments in the muscles of the chest because of hacking are additionally normal. It is significant you examine the agony with your primary care physician on the grounds that despite the fact that it is a typical manifestation of COVID-19 there are other significant things that can cause chest torment ^[46]. Most by far of individuals who are getting COVID-19 are recuperating completely with no enduring impacts. Severe contaminations or those that require ventilation in the emergency unit have consequences for the lungs and muscles because of both the coronavirus and the impacts of being in escalated care ^[47]. Restoration and backing can assist patients with getting back to an ordinary life. This will just influence a little level of patients who get the contamination ^[48]. Much of the time the appropriate response is no. There are cases, especially when patients are admitted to the emergency unit, lost lung limit and lung scarring have occurred after COVID-19 ^[49].

Conclusion

A clinical threat the prevalence of COVID-19 infection has become very population and healthcare staff around the world.

References

1. Zheng, J. (2020). SARS-CoV-2: an emerging coronavirus that causes a global threat. *International journal of biological sciences*, 16(10), 1678.
2. The, L. I. D. (2020). COVID-19, a pandemic or not. *The Lancet. Infectious Diseases*, 20(4), 383.
3. Comas-Garcia, M. (2019). Packaging of genomic RNA in positive-sense single-stranded RNA viruses: A complex story. *Viruses*, 11(3), 253.
4. Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., & Du, B. (2020). Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive care medicine*, 1-34.
5. Khafaie, M. A., & Rahim, F. (2020). Cross-country comparison of case fatality rates of COVID-19/SARS-COV-2. *Osong Public Health and Research Perspectives*, 11(2), 74.
6. Meng, J., Xiao, G., Zhang, J., He, X., Ou, M., Bi, J., & GAO, H. (2020). Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. *Emerging microbes & infections*, 9(1), 757-760.
7. Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Di Napoli, R. (2020). Features, evaluation and treatment coronavirus (COVID-19). In *Statpearls* [internet]. StatPearls Publishing.
8. Chen, Y., Liu, Q., & Guo, D. (2020). Emerging coronaviruses: genome structure, replication, and pathogenesis. *Journal of medical virology*, 92(4), 418-423.
9. Adhikari, S. P., Meng, S., Wu, Y. J., Mao, Y. P., Ye, R. X., Wang, Q. Z., ... & Zhou, H. (2020). Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. *Infectious diseases of poverty*, 9(1), 1-12.
10. Ji, W., Wang, W., Zhao, X., Zai, J., & Li, X. (2020). Cross-species transmission of the newly identified coronavirus 2019-nCoV. *Journal of medical virology*, 92(4), 433-440.
11. Benvenuto, D., Giovanetti, M., Ciccozzi, A., Spoto, S., Angeletti, S., & Ciccozzi, M. (2020). The 2019-new coronavirus epidemic: evidence for virus evolution. *Journal of Medical Virology*, 92(4), 455-459.
12. Chan, J. F. W., Kok, K. H., Zhu, Z., Chu, H., To, K. K. W., Yuan, S., & Yuen, K. Y. (2020). Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerging microbes & infections*, 9(1), 221-236.

13. Cao, Y., Li, L., Feng, Z., Wan, S., Huang, P., Sun, X., & Wang, W. (2020). Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. *Cell Discovery*, 6(1), 1-4.
14. Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive care medicine*, 1-5.
15. Xu, H., Zhong, L., Deng, J., Peng, J., Dan, H., Zeng, X., & Chen, Q. (2020). High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa.
16. Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., & Dighe, A. (2020). Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet infectious diseases*.
17. Murthy, S., Gomersall, C. D., & Fowler, R. A. (2020). Care for critically ill patients with COVID-19. *Jama*, 323(15), 1499-1500.
18. Covid, C. D. C., COVID, C., COVID, C., Chow, N., Fleming-Dutra, K., Gierke, R., & Roguski, K. (2020). Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. *Morbidity and Mortality Weekly Report*, 69(13), 382.
19. He, X. W., Lai, J. S., Cheng, J., Wang, M. W., Liu, Y. J., Xiao, Z. C., ... & Zeng, H. S. (2020). Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients. *Zhonghuanxue Guan Bing zazhi*, 48, E011-E011.
20. Rogers, L. C., Lavery, L. A., Joseph, W. S., & Armstrong, D. G. (2020). All Feet on Deck—The Role of Podiatry during the COVID-19 Pandemic: Preventing hospitalizations in an overburdened healthcare system, reducing amputation and death in people with diabetes. *Journal of the American Podiatric Medical Association*, 0000-0000.
21. Chen, C., Yan, J. T., Zhou, N., Zhao, J. P., & Wang, D. W. (2020). Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. *Zhonghuanxue guan bing zazhi*, 48, E008-E008.
22. Guo, W., Li, M., Dong, Y., Zhou, H., Zhang, Z., Tian, C., & Zhao, L. (2020). Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes/metabolism research and reviews*, e3319.
23. Li, B., Yang, J., Zhao, F., Zhi, L., Wang, X., Liu, L., & Zhao, Y. (2020). Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clinical Research in Cardiology*, 1-8.
24. Muniyappa, R., & Gubbi, S. (2020). COVID-19 pandemic, coronaviruses, and diabetes mellitus. *American Journal of Physiology-Endocrinology and Metabolism*, 318(5), E736-E741.
25. Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. *The Lancet. Respiratory Medicine*, 8(4), e21.
26. Maddaloni, E., & Buzzetti, R. (2020). Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. *Diabetes/Metabolism Research and Reviews*, e33213321.
27. Vuorio, A., Watts, G. F., & Kovanen, P. T. (2020). Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk. *Journal of internal medicine*.
28. Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., & Lu, Z. (2020). Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA cardiology*.
29. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., & Yu, T. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*, 395(10223), 507-513.
30. Pedersen, S. F., & Ho, Y. C. (2020). SARS-CoV-2: a storm is raging. *The Journal of clinical investigation*, 130(5).
31. Zhang, C., Wu, Z., Li, J. W., Zhao, H., & Wang, G. Q. (2020). The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. *International journal of antimicrobial agents*, 105954.

32. South, A. M., Diz, D. I., & Chappell, M. C. (2020). COVID-19, ACE2, and the cardiovascular consequences. *American Journal of Physiology-Heart and Circulatory Physiology*, 318(5), H1084-H1090.
33. Chen, L., Li, X., Chen, M., Feng, Y., & Xiong, C. (2020). The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovascular research*, 116(6), 1097-1100.
34. Sun, M. L., Yang, J. M., Sun, Y. P., & Su, G. H. (2020). Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. *Zhonghua jie he hehu xi zazhi= Zhonghua jie he he huxizazhi= Chinese journal of tuberculosis and respiratory diseases*, 43, E014-E014.
35. Chen, C., Zhang, X. R., Ju, Z. Y., & He, W. F. (2020). Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. *Zhonghua shaoshang zazhi= Zhonghua shaoshang zazhi= Chinese journal of burns*, 36, E005-E005.
36. Xu, L., Liu, J., Lu, M., Yang, D., & Zheng, X. (2020). Liver injury during highly pathogenic human coronavirus infections. *Liver International*, 40(5), 998-1004.
37. Jin, X., Lian, J. S., Hu, J. H., Gao, J., Zheng, L., Zhang, Y. M., ... & Yu, G. D. (2020). Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut*, 69(6), 1002-1009.
38. Nouri-Vaskeh, M., & Alizadeh, L. (2020). Fecal transmission in COVID-19: A potential shedding route. *Journal of Medical Virology*.
39. Hindson, J. (2020). COVID-19: faecal-oral transmission. *Nature Reviews Gastroenterology & Hepatology*, 17(5), 259-259.
40. Gu, J., Han, B., & Wang, J. (2020). COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. *Gastroenterology*, 158(6), 1518-1519.
41. Turner, D., Huang, Y., Martín-de-Carpi, J., Aloï, M., Focht, G., Kang, B., & Pujol-Muncunill, G. (2020). COVID-19 and paediatric inflammatory bowel diseases: Global experience and provisional guidance (March 2020) from the paediatric IBD porto group of ESPGHAN. *Journal of Pediatric Gastroenterology and Nutrition*.
42. Monteleone, G., & Ardizzone, S. (2020). Are patients with inflammatory bowel disease at increased risk for Covid-19 infection. *Journal of Crohn's and Colitis*.
43. GAO, Q. Y., Chen, Y. X., & Fang, J. Y. (2020). 2019 novel coronavirus infection and gastrointestinal tract. *Journal of digestive diseases*, 21(3), 125-126.
44. Chai, X., Hu, L., Zhang, Y., Han, W., Lu, Z., Ke, A., & Cai, J. (2020). Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. *BioRxiv*.
45. Peeri, N. C., Shrestha, N., Rahman, M. S., Zaki, R., Tan, Z., Bibi, S., & Haque, U. (2020). The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned. *International journal of epidemiology*.
46. Hase, R., Kurita, T., Muranaka, E., Sasazawa, H., Mito, H., & Yano, Y. (2020). A case of imported COVID-19 diagnosed by PCR-positive lower respiratory specimen but with PCR-negative throat swabs. *Infectious Diseases*, 52(6), 423-426.
47. Kim, E. S., Chin, B. S., Kang, C. K., Kim, N. J., Kang, Y. M., Choi, J. P., ... & Yun, N. R. (2020). Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. *Journal of Korean medical science*, 35(13).
48. Fu, L., Wang, B., Yuan, T., Chen, X., Ao, Y., Fitzpatrick, T., & Luo, G. (2020). Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. *Journal of Infection*.
49. Zaki, A. M., Van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D., & Fouchier, R. A. (2012). Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *New England Journal of Medicine*, 367(19), 1814-1820.